TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07343960: A Phase I, Single-dose, Non-randomized, Open-label, Parallel Group Study to Assess the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

Sponsor: AstraZeneca · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$3,883,072

Rescue Site Savings

+$2,573,664

Unlock Full NCT07343960 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07343960 Rescue Dossier →